Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

Inclusion Criteria: * male or female ages 18 and up * utilizing a regimen of at least two injections daily of insulin and at least two injections daily of Symlin * able to understand and sign an informed consent form and HIPPA form * agrees to all study visits and procedures * HbA1c between \>6.5 and \<9.0 (inclusive) Exclusion Criteria: * history or current diagnosis of chronic disease which in the view of the PI would interfere with adequate involvement in and completion of the requirements of the study * history of malignancy with in the last five years of study entry (other than basal cell carcinoma) * current use of any drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine), agents that slow intestinal absorption of nutrients (e.g. a-glucosidase inhibitors) or promotility agents (e.g. metaclopromide) * any contraindication of Symlin or I-PORT according to the package labeling * are female and pregnant, lactating or planning to become pregnant during the duration of the trial * are poorly compliant with their current insulin and/or Symlin regimen, as defined by their HCP * has history of known hypersensitivity to plastics or polymers * treatment with any investigational drug within one month prior to enrollment * myocardial infarction or stroke within six months prior to screening * initiated use of Symlin pen or any Insulin pen in lieu of a vial in last 4 weeks (pen use is okay as long as they have been using it for at least 4 weeks prior to screening visit) * female subjects of childbearing potential practicing inadequate birth control (adequate birth control is defined as using oral contraceptives, double barrier methods, Intrauterine devices, surgical sterilization or vasectomized partner) * have confirmed diagnosis of gastroparesis * have hypoglycemia unawareness